Inicio › Mieloma múltiple › Georgia
Ensayos clínicos de Mieloma múltiple en Georgia
49 estudios sobre Mieloma múltiple buscan participantes en Georgia.
Ciudades en Georgia
Texto oficial del estudio (inglés)
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Emory University Hospital Midtown, Atlanta
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07555938A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Winship Cancer Institute of Emory University, Atlanta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT05137054A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Emory University - Winship Cancer Institute, Atlanta
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07393282A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Emory University, Atlanta
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05201781A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- City of Hope Cancer Center, Newnan
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Emory University, Atlanta
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Emory University Winship Cancer Institute, Atlanta
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT04634552Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Emory Winchip Cancer Center, Atlanta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT06433947A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Winship Cancer Institute, Emory University, Atlanta
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07284758A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Winship Cancer Institute, Emory University, Atlanta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07280013AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Atlanta
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT06106945A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Winship Cancer Institute, Emory University, Atlanta
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06615479Collection of Tissue Samples for Cancer Research
- Emory University, Atlanta
ReclutandoEstudio observacional
2 Months · Todos los sexos · Actualizado el 27 oct 2026 · NCT00900198Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Emory University Hospital, Atlanta
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT03761108A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Emory University Winship Cancer Center, Atlanta
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT04973605A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- The Winship Cancer Institute of Emory University, Atlanta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT05651932A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Atlanta
- Research Site, Atlanta
- Research Site, Newnan
ReclutandoFase 3
Edades de 18 a 130 · Todos los sexos · Actualizado el 21 oct 2026 · NCT07735637A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- City Of Hope - Atlanta /ID# 280294, Newnan
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 oct 2026 · NCT07409246A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Winship Cancer Institute of Emory University /ID# 274830, Atlanta
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT06892522A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Winship Cancer Institute of Emory University /ID# 277667, Atlanta
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT07095452A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Atlanta
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT07681596CAR T-cell Therapy in Patients With Renal Dysfunction
- Caitlin Guzowski, Atlanta
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT05909059AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Atlanta
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 oct 2026 · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Winship Cancer Institute of Emory University, Atlanta
- Northside Hospital, Atlanta
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 oct 2026 · NCT06297226Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
- Emory University (Data Collection Only), Atlanta
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT06976476A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Atlanta
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Emory University, Atlanta
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07518186A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
- Winship Cancer Institute Emory University, Atlanta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06768489A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Atlanta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07073547A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Emory University Hospital, Atlanta
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America - Atlanta, Atlanta
- Emory University Winship Cancer Institute, Atlanta
- Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion, Savannah
- y 3 más
ReclutandoFase 2
Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT02693535Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Winship Cancer Institute of Emory University, Atlanta
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT04879043Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
- Emory University/Winship Cancer Institute, Atlanta
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT05208307A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Emory University Hospital, Atlanta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07075185A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Macon
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT07227311Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Atlanta
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT07764978Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
- Emory University Hospital/Winship Cancer Institute, Atlanta
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jul 2026 · NCT07101445A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Northside Hospital, Atlanta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 jul 2026 · NCT06121843Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Emory Winship Cancer Institute, Atlanta
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 jun 2026 · NCT04068597Personalized Autologous Transplant for Multiple Myeloma
- Winship Cancer Institute of Emory University, Atlanta
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 jun 2026 · NCT04483206De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.